CDER Deputy Galson Brings Risk Management Experience To FDA Surveillance
Executive Summary
FDA Center for Drug Evaluation & Research Deputy Director Steven Galson, MD, has experience in public health risk assessment that will contribute to the center's revamping of its postmarketing surveillance program.
You may also be interested in...
Former CDER Chief Galson Moving To Amgen
Galson, who went to FDA in 2001 to deal with post-marketing surveillance issues, will arrive in time for Aranesp advisory committee meeting.
PDUFA’s Fairy Godmother: Woodcock Steps Into Breach As Acting CDER Chief
Faced with the departure of Steven Galson as CDER director just as major new drug safety authorities have been bestowed upon FDA, Commissioner Andrew von Eschenbach has turned to former CDER director Janet Woodcock to provide a practiced hand on the wheel of change until a permanent replacement can be found
PDUFA’s Fairy Godmother: Woodcock Steps Into Breach As Acting CDER Chief
Faced with the departure of Steven Galson as CDER director just as major new drug safety authorities have been bestowed upon FDA, Commissioner Andrew von Eschenbach has turned to former CDER director Janet Woodcock to provide a practiced hand on the wheel of change until a permanent replacement can be found